Day: February 5, 2022

Tomas Venit, Dr. preferred orientation. As a total result, we present that these devices can effectively catch CTCs from sufferers with metastatic and localized prostate cancers through anti-EpCAM, anti-PSA, and anti-PSMA antibodies, which is ideal for AFM measurements of captured intact CTCs. When characterized nanomechanically, CTCs from metastatic cancers demonstrate reduced elasticity and elevated deformability […]